Correction to: Neuroimaging Genomics a Predictor of Major Depressive Disorder (MDD)

被引：0
|
作者：
Manav Jindal
Aakash Chhetri
Abhilash Ludhiadch
Paramdeep Singh
Sameer Peer
Jawahar Singh
Rahatdeep Singh Brar
Anjana Munshi
机构：
[1] All India Institute of Medical Sciences,Department of Radiodiagnosis
[2] Central University of Punjab,Department of Human Genetics and Molecular Medicine
[3] All India Institute of Medical Sciences,Department of Psychiatry
[4] Homi Bhabha Cancer Hospital & Research Center,Department of Diagnostic and Interventional Radiology
来源：
Molecular Neurobiology | 2024年 / 61卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3441 / 3441
相关论文
共 50 条
  • [31] Response to D-amphetamine is altered in major depressive disorder (MDD).
    Tremblay, LK
    Busto, U
    Naranjo, CA
    Cardenas, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 130 - 130
  • [32] Volume of the midbrain dorsal raphe nucleus in major depressive disorder (MDD)
    Stockmeier, CA
    Saenz, MD
    Smith, E
    Miguel-Hidalgo, JJ
    Friedman, L
    Rajkowska, G
    BIOLOGICAL PSYCHIATRY, 2005, 57 (08) : 183S - 183S
  • [33] Brain-Derived Neurotrophic Factor (BDNF) as a Predictor of Treatment Response in Major Depressive Disorder (MDD): A Systematic Review
    Zelada, Mario Ignacio
    Garrido, Veronica
    Liberona, Andres
    Jones, Natalia
    Zuniga, Karen
    Silva, Hernan
    Nieto, Rodrigo R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (19)
  • [34] Blunted d-amphetamine response in major depressive disorder (MDD).
    Tremblay, LK
    Naranjo, CA
    Busto, U
    Cardenas, L
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (02) : 141 - 141
  • [35] Major depressive disorder (mdd): emerging immune targets at preclinical level
    Varma, Manasi
    Kaur, Arshpreet
    Bhandari, Ranjana
    Kumar, Ashwani
    Kuhad, Anurag
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2023, 27 (06) : 479 - 501
  • [36] COST AND RESOURCE USE OF MANAGING MAJOR DEPRESSIVE DISORDER (MDD) IN CHINA
    Low, W.
    Azmi, S.
    Yee, S. L.
    Abdat, A.
    Yang, Y.
    Milea, D.
    VALUE IN HEALTH, 2014, 17 (07) : A768 - A769
  • [37] Adjunctive aripiprazole in major depressive disorder (MDD): efficacy and predictors of remission
    Nelson, J. C.
    Thase, M. E.
    Baker, R. A.
    Rollin, L. M.
    McQuade, R. D.
    Marcus, R. N.
    Berman, R. M.
    Wisniewski, S. R.
    Gismondi, R.
    Loze, J. Y.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2010, 20 : S386 - S386
  • [38] Efficacy and safety of sertraline in the treatment of pediatric major depressive disorder (MDD)
    Wagner, K
    Donnelly, C
    Wohlberg, C
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2002, 12 : S231 - S232
  • [39] ECONOMIC ANALYSIS OF ESCITALOPRAM (GENERIC DRUG) IN MAJOR DEPRESSIVE DISORDER (MDD)
    Walczak, J.
    Nogas, G.
    Garbacka, M.
    Obrzut, G.
    Pieniazek, I
    VALUE IN HEALTH, 2010, 13 (03) : A114 - A114
  • [40] Longitudinal assessment of sleep neurophysiology in adolescent major depressive disorder (MDD)
    Castiglione, Chiara
    Markovic, Andjela
    Wild, Salome
    Zarafeta, Dimitra
    Kaess, Michael
    Tarokh, Leila
    JOURNAL OF SLEEP RESEARCH, 2024, 33
12345